Drug intelligence / Profile preview

StromaCel

Development stage: Preclinical
Lead developer: StromaCel
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

**StromaCel** is a developmental mesenchymal stromal cell (MSC)-based therapy from StromaCel, Inc., aimed at treating cardiovascular disease and conditions following post-MI injury in patients. It leverages MSCs, likely derived from bone marrow or similar sources, to promote tissue repair and immunomodulation through paracrine effects and secretion of anti-inflammatory factors, though specific mechanisms, clinical data, and development status remain limited in public records.[16]

Beyond the preview

Go deeper on StromaCel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StromaCel.

Explore the full profile